Quintiles honored as Best CRO in Asia
Thursday, March 31, 2016
Quintiles has been named the Best CRO in Asia at the 2016 BioPharma Asia Industry Awards, winning the honor for the fourth time in the event’s six-year history. The award goes to the CRO that best demonstrates an ongoing commitment to improving clinical research services in Asia and reducing lead times for customers.
“More than 1,000 votes were cast in the Best CRO category, and Quintiles was the overwhelming favorite,” said Sharon Roessen, managing director of Terrapinn, organizer of BioPharma Asia Convention 2016. “In addition to reducing lead times and advancing clinical research, Quintiles was chosen for its ability to deliver end-to-end solutions for customers and its outstanding thought leadership. Quintiles has clearly elevated clinical research standards in Asia-Pacific.”
Accepting the award was Dr. Ken Lee, Quintiles chief medical officer, Asia-Pacific, who said: “I accept this award on behalf of our 12,000-plus Quintiles professionals across Asia-Pacific who work tirelessly to speed the development of new and better medicines. We’re driven by our desire to help our customers improve their probability of success. We never lose sight of the patient—their lives depend on us.”
Over the past 18 months, Quintiles has continued to enhance its integrated services in the region:
- Launched a custom-tailored solution set for Asia-Pacific emerging biopharma companies.
- Released “Investigator Initiated Clinical Trials Made Easy,” a handbook to foster the growth of such trials in Asia-Pacific, which play a vital role in improving and expanding patient care.
- Expanded its dedicated unit offering medical devices and diagnostics trials in the region, including release of a white paper about “Balancing risk and reward” in the MD&D market here.
- Opened a new Greater China Regional Headquarters in Shanghai, enhancing its ability to help local companies expand and multinationals succeed in the world’s 2nd largest biopharma market.
- Became the first CRO in Japan to establish a regenerative medicine center of excellence (in the Kobe Biomedical Innovation Cluster) focused on designing regulatory pathways and the complex clinical studies for this new generation of therapies.